Clovis And Avila Join In Oncology Drug/Diagnostic Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
One year after securing startup financing, Clovis has acquired rights to a second program, this time Avila's EGFR mutant-selective inhibitor program.
You may also be interested in...
Avila/Clovis Partnership Moves To The Clinic
Avila and Clovis have selected a drug candidate to move into human testing.
Avila/Clovis Partnership Moves To The Clinic
Avila and Clovis have selected a drug candidate to move into human testing.
Sanofi Bulks Up Oncology Development With Avila Collaboration
Sanofi-Aventis adds to its expertise in oncology by striking a deal with Massachusetts-based Avila Therapeutics for the biotech's covalent-bonding technology in a deal that could be worth up to $800 million.